1) Bernson-Leung ME, Leung LY, Kumar S:Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis 23:1239-1241, 2014
2) De Meijer AR, Fikkers BG, de Keijzer MH, van Engelen BG, Drenth JP:Serum creatine kinase as predictor of clinical course in rhabdomyolysis:a 5-year intensive care survey. Intensive Care Med 29:1121-1125, 2003
3) Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D:Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use. Clin Schizophr Relat Psychoses 21:1-13, 2013
4) Every-Palmer S:Synthetic cannabinoid JWH-018 and psychosis:an explorative study. Drug Alcohol Depend 117:152-157, 2011
5) Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL:“Spice” and “K2” herbal highs:a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320-326, 2012
6) Holt SG, Moore KP:Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 27:803-811, 2001
7) 小宮山 豊,遠藤容子:日本中毒情報センターの役割と活用法.Medical Technology 41:1180-1185, 2013
8) 松本俊彦,谷渕由布子,高野 歩,小林桜児,和田 清:全国の精神科医療施設における薬物関連精神疾患の実態調査.平成24年度厚生労働科学研究費補助金(医薬品・医療機器等レギュラトリーサイエンス総合研究事業)分担研究報告書
9) McMahon GM, Zeng X, Waikar SS:A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med 173:1821-1827, 2013
10) Melli G, Chaudhry V, Cornblath DR:Rhabdomyolysis:an evaluation of 475 hospitalized patients. Medicine(Baltimore)84:377-385, 2005
11) Woodrow G, Brownjohn AM, Turney JH:The clinical and biochemical features of acute renal failure due to rhabdomyolysis. Ren Fail 17:467-474, 1995